Press Releases April 24, 2026 06:45 AM

W&T Offshore Announces Timing of First Quarter 2026 Earnings Release and Conference Call

W&T Offshore Schedules Q1 2026 Earnings Release and Conference Call

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
WTI

W&T Offshore, Inc., an independent oil and natural gas producer operating primarily in the Gulf of Mexico, announced it will release its first quarter 2026 earnings on May 7, 2026, after market close, followed by a conference call on May 8, 2026. The company operates numerous offshore fields and holds significant acreage leases in the Gulf region.

W&T Offshore Announces Timing of First Quarter 2026 Earnings Release and Conference Call
WTI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • W&T Offshore will release Q1 2026 earnings on May 7, 2026, after NYSE market close.
  • A conference call discussing financial and operational results is scheduled for May 8, 2026.
  • W&T Offshore operates 49 fields and holds approximately 624,700 gross acres of offshore leases in the Gulf of Mexico region, focusing on oil and natural gas production.

HOUSTON, April 24, 2026 (GLOBE NEWSWIRE) -- W&T Offshore, Inc. (NYSE: WTI) (the “Company”) today announced the timing of its first quarter 2026 earnings release and conference call.

The Company said it will issue its first quarter 2026 earnings release on Thursday, May 7, 2026, after the close of trading on the NYSE and host a conference call to discuss financial and operational results on Friday, May 8, 2026, at 9:00 a.m. Central Time (10:00 a.m. Eastern Time).

Interested parties may participate by dialing (844) 739-3797. International parties may dial (412) 317-5713. Participants should request to be joined to the “W&T Offshore, Inc. Conference Call.” This call will also be webcast and available on W&T Offshore’s website at www.wtoffshore.com under “Investors.” An audio replay will be available on the Company’s website following the call.

About W&T Offshore

W&T Offshore, Inc. is an independent oil and natural gas producer with operations offshore in the Gulf of America and has grown through acquisitions, exploration and development. As of December 31, 2025, the Company had working interests in 49 fields in federal and state waters (which include 42 fields in federal waters and seven in state waters). The Company has under lease approximately 624,700 gross acres (490,200 net acres) spanning across the outer continental shelf off the coasts of Louisiana, Texas, Mississippi and Alabama, with approximately 477,200 gross acres on the conventional shelf, approximately 141,900 gross acres in the deepwater and 5,600 gross acres in Alabama state waters. A majority of the Company’s daily production is derived from wells it operates. For more information on W&T, please visit the Company’s website at www.wtoffshore.com.

CONTACTS:Al Petrie
Investor Relations Coordinator
investorrelations@wtoffshore.com
713-297-8024Sameer Parasnis
Executive VP and CFO 
sparasnis@wtoffshore.com
713-513-8654



Risks

  • Earnings could be impacted by volatile commodity prices affecting the oil and natural gas market.
  • Operational risks inherent in offshore production such as weather, regulatory, and environmental factors.
  • Market reaction may depend on production volumes and financial performance relative to expectations, which can fluctuate due to external economic and geopolitical factors.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026